Vericel
VCEL46.6701.54% ( +0.710 )
Vericel (VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and...
- Open
- 45.980
- High
- 47.130
- Low
- 45.980
- Prev. Close
- 45.960
- Volume
- 49.95K
- Turnover
- 2.33M
- Avg Price
- 46.573
- Bid/Ask Ratio
- --
- Amplitude
- 2.50%
- 52wk High
- 49.320
- Volume Ratio
- 0.59
- Turnover Ratio
- 0.10%
Vericel Analyst Rating
View MoreForecast & Rating
Jul 31, 2026Price forecast
$60.5729.79%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy0.00%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 2 days ago, 03:06 PM
Vericel Principal Accounting Officer Jonathan Siegal disposes of 4,500 common shares worth $220,050
- Tip Ranks · Jul 31 at 06:47 AM
Truist Financial Reaffirms Their Buy Rating on Vericel (VCEL)
- TradingView · Jul 30 at 07:51 AM
Vericel Corp 2Q 2026: Revenue $77.46M, EPS $0.04— 10-Q Summary
- Earnings Watch · Jul 30 at 07:06 AM
Vericel | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 77.46 M
- StockTitan · Jul 29 at 10:55 PM
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | VCEL Stock News
- MSN · Jul 29 at 10:02 AM
Vericel Q2 2026 earnings preview
